retatrutide trial safety Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 retatrutide safety trial results Retatrutide

However, retatrutide has not yet received regulatory approval from the MHRA, EMA, or FDA, meaning no licensed dosage currently exists

Frequently asked questions Can I use semaglutide a few days after its expiration date

The 2.4 mg maintenance dose is close to the 1 mL capacity of a standard U-100 insulin syringe, which is why some community sources reconstitute cagrilintide at higher concentration (e.g., 5 mg in 1.5 mL 3.33 mg/mL 2.4 mg = 0.72 mL = 72 units) to keep dose volume manageable

Its effect on total body fat, as opposed to visceral fat specifically, is also less pronounced than the GLP-1 class compounds